Mosaic variegated aneuploidy syndrome is a rare autosomal recessive genetic disorder that causes inappropriate chromosomal segregation in mitosis process and because of it, some cells are aneuploid (mosaic). It is caused by mutation BUB1, BUB1B, BUB3, CEP57 or TRIP13. Person with MVA can present with IUGR, microcephaly and a wide range of congenital abnormalities.
Symptoms Signs of this disease are: Very frequent:
Peritoneal fluid excess Cataracts Dandy-Walker malformation Epicanthus Glaucoma Micrognathia Increased nuchal translucency Short stature Ventriculomegaly Frequent:
Eye and vision abnormalities Global developmental delay Microcephaly Intellectual disability Triangular facies Occasional:
Anomalies of aortic morphology Anomalies of cardiovascular system morphology Lung lobation abnormality Abnormalities of skull Abnormality of immune system Anomalies of skin pigmentation Anomalies of the skeletal system Atypical genitalia Agenesis (or hypoplasia) of the cerebellum and the corpus callosum Sleep apnea Cleft palate 5th finger clinodactyly Tall forehead Hypothyroidism Wide nose Sloping forehead Some form of tumors, such as: Acute lymphoblastic leukemia, Nephroblastoma, Rhabdomyosarcoma. Depressed nasal ridge Down-slanting palpebral fissures Intrauterine growth restriction
Cause This disorder is caused by defect of genes that are responsible for spindle checkpoint. Types include:
Also those genes are associated with that disorder: BUB3 and BUB1.
Pathophysiology BUB1, BUB1B and BUB3 participates in spindle checkpoint checkpoint process which is necessary for correct chromosome splitting process in mitosis, consequently mutation of those 3 genes causes incorrect splitting of chromosomes. CENATAC gene is responsible for minor (U12‐dependent) spliceosome, which is important for cell cycle regulation proteins and in MVA, this process is deregulated. CEP57 plays role in spindle pole integrity, which mutation can cause incorrect segregation during mitosis. SLF2 and SMC5 are necessary for proper chromosomal segregation through centromeric and sister chromatid cohesion, consequently this mechanism is disrupted in this disease. TRIP13 also participates in spindle checkpoint process by activating MAD2 and that activates spindle checkpoint and mutations in TRIP13 can cause MVA .
Diagnosis MVA can be suspected by phenotype and confirmed by karyotyping and genetic testing.
Karyotyping is a process, when person's chromosomes are getting isolated and ordered in numerical order, consequently it can be checked for any anomalies. Genetic testing is a process when person's blood or other tissue gets inspected to determine changes in their genes.
Prognosis The prognosis of MVA syndrome depends on the types of malformation presented in the individual.
History The first mention of MVA was made by Rudd and colleagues in 1983, although Warburton and colleagues coined the name of MVA in 1991.
Prevalence The prevalence of that disorder is 1/1,000,000.
References